Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.71
$4.41
$1.35
▼
$50.10
$3.66M1.04227,964 shsN/A
BioVie Inc. stock logo
BIVI
BioVie
$1.60
-0.7%		$1.68
$0.82
▼
$3.79
$13.52M0.741.67 million shs429,668 shs
HIND
Vyome
$2.04
-1.0%		$2.13
$1.75
▼
$6.56
$14.32M1.5302,564 shs2,814 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.12
-1.8%		$1.11
$0.54
▼
$1.87
$13.72M0.567,987 shs1,070 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%0.00%
BioVie Inc. stock logo
BIVI
BioVie
-1.23%-9.55%-22.97%-17.22%-13.44%
HIND
Vyome
+2.49%+5.10%-7.46%-4.63%-62.27%
Synlogic, Inc. stock logo
SYBX
Synlogic
-0.87%-1.72%-5.79%+67.65%-33.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.71
$4.41
$1.35
▼
$50.10
$3.66M1.04227,964 shsN/A
BioVie Inc. stock logo
BIVI
BioVie
$1.60
-0.7%		$1.68
$0.82
▼
$3.79
$13.52M0.741.67 million shs429,668 shs
HIND
Vyome
$2.04
-1.0%		$2.13
$1.75
▼
$6.56
$14.32M1.5302,564 shs2,814 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.12
-1.8%		$1.11
$0.54
▼
$1.87
$13.72M0.567,987 shs1,070 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%0.00%
BioVie Inc. stock logo
BIVI
BioVie
-1.23%-9.55%-22.97%-17.22%-13.44%
HIND
Vyome
+2.49%+5.10%-7.46%-4.63%-62.27%
Synlogic, Inc. stock logo
SYBX
Synlogic
-0.87%-1.72%-5.79%+67.65%-33.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00
N/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
HIND
Vyome
2.50
Moderate Buy$9.25353.43% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest APTO, HIND, SYBX, and BIVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$1.36 per shareN/A
HIND
Vyome
$320K44.75N/AN/A$0.67 per share3.04
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,714.86N/AN/A$1.09 per share1.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
BioVie Inc. stock logo
BIVI
BioVie
-$22.07M-$3.15N/AN/AN/AN/A-126.02%-108.88%11/9/2026 (Estimated)
HIND
Vyome
-$10.26M-$3.37N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$0.06N/AN/AN/AN/A-26.47%-18.00%11/11/2026 (Estimated)

Latest APTO, HIND, SYBX, and BIVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52-$0.70-$0.18-$0.70N/AN/A
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
BioVie Inc. stock logo
BIVI
BioVie
N/A
3.59
3.59
HIND
Vyome
N/A
4.37
4.37
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.65
2.65

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
HIND
Vyome
22.06%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.33%
BioVie Inc. stock logo
BIVI
BioVie
0.90%
HIND
Vyome
33.00%
Synlogic, Inc. stock logo
SYBX
Synlogic
2.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
BioVie Inc. stock logo
BIVI
BioVie
138.45 million8.38 millionNo Data
HIND
Vyome
187.02 million4.70 millionN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
8012.25 million11.39 millionNo Data

Recent News About These Companies

Synlogic (NASDAQ:SYBX) and Inovio Pharmaceuticals (NASDAQ:INO) Head to Head Contrast
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037249
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
September 16, 2026  |  defenseworld.netD
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH)
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352812/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-varex-imaging-corporation-nasdaq-vrex-synlogic-inc-otc-sybx-bowman-consulting-group-ltd-nasdaq-.html
SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders
August 10, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/10/10427797.htm
Synlogic and Caldera Therapeutics announce merger and $278 million private placement
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/synlogic-and-caldera-therapeutics-announce-merger-and-278-million-private-placement/ar-AA28Zdef
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
July 29, 2026  |  aol.comA
Synlogic's Strategic Crossroads: A Company in Limbo
February 10, 2026  |  aktiencheck.deA
Synlogic Challenges Nasdaq Delisting Notice
November 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/synlogic-challenges-nasdaq-delisting-notice?utm_source=marketbeat.com&utm_medium=referral
We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth
September 18, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/think-synlogic-nasdaq-sybx-afford-105816457.html
Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance
June 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SYBX/news/
Synlogic's executive sells shares worth $2,802
February 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/synlogic-s-executive-sells-shares-worth-2-802/ar-AA1yq62c
Synlogic Reports Q3 2024 Financial Outcomes
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/synlogic-reports-q3-2024-financial-outcomes-1034015193
Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results
November 13, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63800545-synlogic-inc-synlogic-reports-third-quarter-2024-financial-results-399.htm
Synlogic Reports Third Quarter 2024 Financial Results
November 12, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/12/2979778/0/en/synlogic-reports-third-quarter-2024-financial-results.html
Synlogic preps phenylketonuria drug for phase 3 after mid-stage win
November 6, 2024  |  pharmaphorum.comP
Synlogic, Inc. (0A8U.L)
August 24, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/0A8U.L/news/
MIN.SG,0P0001I7V6,0 (MIN.SG)
August 16, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/MIN.SG/chart/
Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty
August 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maintaining-hold-on-synlogic-amid-strategic-reassessment-and-financial-uncertainty-1033683377
Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results
August 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/62948190-synlogic-inc-synlogic-reports-second-quarter-2024-financial-results-399.htm
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
August 8, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/08/sybx-stock-earnings-synlogic-for-q2-of-2024/?cc=marketbeat&cp=pdtk

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
J.M. Smucker logo card on a table with jam, peanut butter, coffee, strawberries, and toast.
J.M. Smucker Stock's Rally Has More Than Tariffs Behind It
By Chris Markoch | September 2, 2026
A Zoox autonomous vehicle drives on a city street in front of an Amazon office building with logo.
Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
By Sam Quirke | August 29, 2026
Vertiv logo displayed in a data center aisle lined with server racks and power equipment.
Vertiv’s UIG Deal Targets the Next Big Constraint in AI Data Centers
By Chris Markoch | September 4, 2026
A Generac home standby generator installed outside a residential house at dusk, connected to an electrical panel.
Generac Plugs Into Amazon for an $8B AI-Powered Deal
By Jeffrey Neal Johnson | September 18, 2026
Fabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
Fabrinet, Dycom, and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
By Bridget Bennett | September 14, 2026
Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

BioVie stock logo

BioVie NASDAQ:BIVI

$1.60 -0.01 (-0.68%)
As of 02:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Vyome NASDAQ:HIND

$2.04 -0.02 (-0.97%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.12 -0.02 (-1.75%)
As of 12:08 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas